CRISPR Therapeutics AG (CRSP) Asset Writedowns and Impairment (2020)

CRISPR Therapeutics AG (CRSP) reported Asset Writedowns and Impairment of $90000.0 for Q3 2020, up 9100.0% sequentially from -$1000.0 in Q2 2020.

CRISPR Therapeutics AG (CRSP) Asset Writedowns and Impairment (2020) Analysis & Trends

CRISPR Therapeutics AG (CRSP) has 1 years of Asset Writedowns and Impairment data on file, last reported at $90000.0 in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	66,140.12 Bn	66,139.83 Bn	-
2	Nanobiotix	1,912.79 Bn	1,912.73 Bn	-
3	Akari Therapeutics	1,022.34 Bn	1,022.34 Bn	-
4	BeOne Medicines	472.60 Bn	467.81 Bn	1.35 Bn
5	Vertex Pharmaceuticals	122.34 Bn	115.09 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	70.14 Bn	61.39 Bn	3.31 Bn
7	Belite Bio	62.79 Bn	62.79 Bn	-
8	Argenx Se	56.19 Bn	51.00 Bn	1.41 Bn
9	Alnylam Pharmaceuticals	37.50 Bn	34.49 Bn	959.66 Mn
10	CRISPR Therapeutics AG	4.56 Bn	4.56 Bn	-

Download Data